Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
In development
Reference number: GID-TA10542
Expected publication date: TBC
As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma. Following an update from the company, the timelines for this appraisal are to be confirmed in order to align with latest regulatory expectations. Therefore, NICE will continue to monitor development and will update interested parties as and when the situation changes.